Status:

COMPLETED

Functional Neuroimaging in Depression

Lead Sponsor:

University Hospital, Ghent

Collaborating Sponsors:

Fund for Scientific Research, Flanders, Belgium

H. Lundbeck A/S

Conditions:

Major Depression

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

Brief Summary

Oral administration of escitalopram during 8 weeks; PET scan with 18F-FDG at inclusion and after 8 weeks

Eligibility Criteria

Inclusion

  • Major Depression, Depressive episode, following DSM-IV criteria
  • MADRS-score \> 25
  • Age: 18-65 yrs
  • Medication-free or anti-depressant wash-out 7 days (for fluoxetine: 6 weeks)
  • Lorazepam 1mg or zolpidem 10mg are allowed

Exclusion

  • Suicidality
  • Bipolar disorder, following DSM-IV criteria
  • Psychotic symptoms
  • Substance abuse
  • Personality disorder, following DSM-IV criteria
  • Cognitive dysfunction due to trauma capitis or dementia
  • Diabetes mellitus
  • Women without contraceptive protection, with pregnancy or breast feeding
  • Pharmacological treatment or ingestion of substance that can influence cerebral perfusion less than a month before inclusion
  • IQ below 80
  • Conditions not compatible with SPC

Key Trial Info

Start Date :

March 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 1 2009

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT00343070

Start Date

March 1 2007

End Date

October 1 2009

Last Update

August 31 2010

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

University Hospital Ghent

Ghent, Belgium, 9000

2

AZ Groeninge campus Sint Maarten

Kortrijk, Belgium, 8500